Table 1.
Summary of the patient’s serological test results before and after relapse of EC-PEL
| Laboratory results | 16 May 2019 | 27 September 2019 | 17 October 2019 | 30 October 2019 | 19 December 2019 | 10 January 2020 | 7 February 2020 | 4 August 2020 |
| Timeline of evaluation and intervention | Routine blood test | Routine blood test | Injection of penicillin started | Follow-up blood test | Follow-up blood test | LD infused (first dose) | LD infused (second dose) |
Routine blood test |
| Hb (g/L) | 147 | 136 | – | 140 | 143 | 150 | 151 | 155 |
| LDH (U/L) | ND | 143 | – | ND | 113 | 115 | ND | 145 |
| AST (U/L) | 18 | 69 | – | 14 | 19 | 18 | 38 | 21 |
| β2M (mg/L) | 3.2 | 5.6 | – | 3.7 | 3.5 | 3.2 | 3.2 | ND |
| CRP (mg/L) | ND | 62.8 | – | 1.6 | 1 | 1.3 | 1.2 | 0.9 |
| Creatinine (μmol/L) | 74 | 75 | – | 70 | 74 | 77 | 83 | ND |
| RPR (titre) | Negative | ND | 1:128 | ND | 1:8 | 1:2 | 1:2 | ND |
| CD4 (cells×106/L) | 125 | 59 | – | 109 | 113 | ND | ND | ND |
| HIV VL (copies/mL) | <20 | <20 | – | 56 | <20 | ND | 61 | <20 |
| HHV8 PCR* | ND | Positive | – | ND | ND | Positive | ND | Negative |
| EBV PCR (copies/mL) | 5248 | ND | – | ND | 5754 | ND | ND | 2239 |
| CMV PCR (copies/mL) | ND | ND | – | ND | <50 | ND | ND | ND |
*HHV8 PCR results were not quantitative.
AST, aspartate aminotransferase; CMV, cytomegalovirus; CRP, C reactive protein; EBV, Epstein-Barr virus; EC-PEL, extracavitary primary effusion lymphoma; Hb, haemoglobin; HHV8, human herpes virus-8; LD, liposomal doxorubicin; LDH, lactate dehydrogenase; β2M, β2 microglobulin; ND, not done; RPR, rapid plasma reagin; VL, viral load.